D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 68 Citations 29,220 252 World Ranking 1676 National Ranking 827

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Immune system

His scientific interests lie mostly in Immunology, Immunotherapy, Melanoma, Immune checkpoint and Cancer research. His research investigates the connection between Immunology and topics such as Cytotoxic T cell that intersect with problems in T cell and Myeloid-derived Suppressor Cell. His work deals with themes such as Endogenous retrovirus and Immunogenicity, which intersect with Immunotherapy.

Taha Merghoub combines subjects such as MEK inhibitor, MAPK/ERK pathway, V600E and Checkpoint Blockade Immunotherapy with his study of Melanoma. His research in Immune checkpoint intersects with topics in Interferon, Interferon type I and Cancer immunotherapy. His Cancer research research is multidisciplinary, incorporating perspectives in Transcription, Repressor and Innate immune system, Innate lymphoid cell.

His most cited work include:

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer (4293 citations)
  • Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma (2586 citations)
  • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (1503 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Cancer research, Immunology, Immune system, Immunotherapy and T cell. Taha Merghoub studies Cancer research, namely Melanoma. Immunology is closely attributed to Cytotoxic T cell in his work.

His Immunotherapy study combines topics from a wide range of disciplines, such as Lung cancer, Myeloid-derived Suppressor Cell, KRAS and Immunogenicity. His T cell research incorporates themes from Priming and Cell biology. His Immune checkpoint study deals with Oncolytic virus intersecting with Intratumoral Therapy.

He most often published in these fields:

  • Cancer research (53.47%)
  • Immunology (38.61%)
  • Immune system (34.65%)

What were the highlights of his more recent work (between 2019-2021)?

  • Cancer research (53.47%)
  • Immunotherapy (32.34%)
  • Immune checkpoint (26.07%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Cancer research, Immunotherapy, Immune checkpoint, Immune system and T cell. His Cancer research research focuses on Melanoma in particular. Taha Merghoub interconnects Cancer cell and Vaccinia in the investigation of issues within Immune checkpoint.

His work on CD8 as part of general Immune system study is frequently linked to Population, therefore connecting diverse disciplines of science. His research on CD8 concerns the broader Immunology. The T cell study combines topics in areas such as Innate immune system, Antigen, Immunogenicity and Cancer immunotherapy.

Between 2019 and 2021, his most popular works were:

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (106 citations)
  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (106 citations)
  • ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity (57 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Immune system

Immunotherapy, Cancer research, Blockade, CD8 and Immune system are his primary areas of study. The various areas that he examines in his Immunotherapy study include T cell, Lung cancer, Oncology and Immunogenicity. His Cancer research study incorporates themes from Tumor microenvironment, Downregulation and upregulation, Antigen and Mutation.

His Blockade research includes themes of Neoadjuvant therapy, Major Pathologic Response, Carcinoma, T-cell receptor and Biomarker. Specifically, his work in Immune system is concerned with the study of Immune checkpoint. His Immune checkpoint study combines topics in areas such as Non small cell, Cell and Long term response.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg.
Science (2015)

6624 Citations

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan.
The New England Journal of Medicine (2014)

3796 Citations

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov.
Science (2016)

2324 Citations

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Katherine B. Chiappinelli;Pamela L. Strissel;Alexis Desrichard;Huili Li.
Cell (2015)

1284 Citations

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Patrick M. Forde;Jamie E. Chaft;Kellie N. Smith;Valsamo Anagnostou.
The New England Journal of Medicine (2018)

1277 Citations

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila.
Journal of Clinical Oncology (2018)

1171 Citations

Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

Sergio A. Quezada;Tyler R. Simpson;Karl S. Peggs;Taha Merghoub.
Journal of Experimental Medicine (2010)

829 Citations

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

Vinod P. Balachandran;Marta Łuksza;Julia N. Zhao;Vladimir Makarov.
Nature (2017)

708 Citations

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Matthew D. Hellmann;Tavi Nathanson;Hira Rizvi;Benjamin C. Creelan.
Cancer Cell (2018)

679 Citations

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

Dmitriy Zamarin;Dmitriy Zamarin;Rikke B. Holmgaard;Rikke B. Holmgaard;Sumit K. Subudhi;Joon Seok Park;Joon Seok Park.
Science Translational Medicine (2014)

663 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Taha Merghoub

Jedd D. Wolchok

Jedd D. Wolchok

Cornell University

Publications: 103

Charles Swanton

Charles Swanton

The Francis Crick Institute

Publications: 82

Matthew D. Hellmann

Matthew D. Hellmann

Memorial Sloan Kettering Cancer Center

Publications: 79

Guido Kroemer

Guido Kroemer

Sorbonne University

Publications: 78

Lorenzo Galluzzi

Lorenzo Galluzzi

Cornell University

Publications: 70

Pier Paolo Pandolfi

Pier Paolo Pandolfi

Beth Israel Deaconess Medical Center

Publications: 69

Eliezer M. Van Allen

Eliezer M. Van Allen

Harvard University

Publications: 67

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 65

Michael A. Postow

Michael A. Postow

Memorial Sloan Kettering Cancer Center

Publications: 61

Mark J. Smyth

Mark J. Smyth

QIMR Berghofer Medical Research Institute

Publications: 60

Jennifer A. Wargo

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

Publications: 59

Douglas B. Johnson

Douglas B. Johnson

Vanderbilt University Medical Center

Publications: 59

Richard A. Scolyer

Richard A. Scolyer

Royal Prince Alfred Hospital

Publications: 56

Timothy A. Chan

Timothy A. Chan

Memorial Sloan Kettering Cancer Center

Publications: 55

Laurence Zitvogel

Laurence Zitvogel

University of Paris-Saclay

Publications: 51

Ignacio I. Wistuba

Ignacio I. Wistuba

The University of Texas MD Anderson Cancer Center

Publications: 51

Trending Scientists

Miguel Nussbaum

Miguel Nussbaum

Pontificia Universidad Católica de Chile

Piet Rietveld

Piet Rietveld

Vrije Universiteit Amsterdam

Gilles Mailhot

Gilles Mailhot

Centre national de la recherche scientifique, CNRS

Reiner Siebert

Reiner Siebert

University of Ulm

André Sentenac

André Sentenac

French Alternative Energies and Atomic Energy Commission

P.W. Froneman

P.W. Froneman

Rhodes University

Tianhong Dai

Tianhong Dai

Harvard University

Toshiharu Hase

Toshiharu Hase

Osaka University

Franco Zunino

Franco Zunino

University of Milan

Rainer Schulin

Rainer Schulin

ETH Zurich

Jeffrey M. Novak

Jeffrey M. Novak

United States Department of Agriculture

Thomas Karl

Thomas Karl

University of Innsbruck

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Volker Wulf

Volker Wulf

University of Siegen

Dirk Ifenthaler

Dirk Ifenthaler

University of Mannheim

Michael Prendergast

Michael Prendergast

University of California, Los Angeles

Something went wrong. Please try again later.